The global Biopsy Devices Market, valued at US$6.86 billion in 2023, is forecasted to grow at a robust CAGR of 7.2%, reaching US$7.27 billion in 2024 and an impressive US$11.01 billion by 2030. The ...

The global Biopsy Devices Market, valued at US$6.86 billion in 2023, is forecasted to grow at a robust CAGR of 7.2%, reaching ...

The global Biopsy Devices Market, valued at US$6.86 billion in 2023, is forecasted to grow at a robust CAGR of 7.2%, reaching US$7.27 billion ...

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...

DELRAY BEACH, Fla., Feb. 25, 2025 /PRNewswire/ -- The global endoscopic ultrasonography market, valued at US$1.28 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching US$1.37 ...

Based on product, the endoscopic ultrasonography market is divided into endoscopes, ultrasound processors, ultrasound probes, ...

The global biosurgery market is projected to grow at a CAGR of 5% from 2025 to 2030. This growth is driven by the increasing ...

On Tuesday, Raymond (NSE:RYMD) James maintained a Market Perform rating on Medtronic , Inc. (NYSE:MDT) following the company’s mixed fiscal third-quarter results. The healthcare giant, currently ...

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information ...

Medtronic Q3 revenue of $8.29 billion missed estimates, but EPS of $1.39 beat the $1.36 consensus. Medtronic reaffirms FY25 organic growth guidance of 4.75%-5%. Our ...

On Tuesday, Raymond (NSE:RYMD) James maintained a Market Perform rating on Medtronic , Inc. (NYSE:MDT) following the company’s mixed fiscal third-quarter results. The healthcare giant ...